Skip to content

New Techniques for Diagnosis and Treatment of Cognitive Impairment in Affective Disorder

Research on New Techniques for Diagnosis and Treatment of Neuropsychiatric Diseases - Research on New Techniques for Diagnosis and Treatment of Affective Disorders and Cognitive Impairment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05596461
Enrollment
90
Registered
2022-10-27
Start date
2022-01-01
Completion date
2024-10-01
Last updated
2023-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Affective Disorder

Brief summary

The purpose of this study is to explore the pathological mechanism of cognitive impairment in patients with affective disorder based on brain gut axis research, preliminarily verify the clinical efficacy of new neural regulation technology on cognitive impairment, and establish an evaluation model to predict the efficacy of physical therapy for affective disorder.

Interventions

DEVICETranscranial magnetic stimulation

Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.

DEVICETranscranial direct current stimulation

Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.

Sponsors

First Affiliated Hospital of Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age 16-65 years old, regardless of gender; 2. Meet DSM-V diagnostic criteria for depression or bipolar disorder; 3. Duration of stable period ≥ 3 months; 4. Young Mania Rating Scale (YMRS) ≤ 6 points; 5. Hamilton Depression Rating Scale 17 - item (HDRS-17) score ≤ 7; 6. The score of cognitive defects questionnaire (PDQ) ≥ 17; 7. Han nationality, right-handed; 8. More than 9 years of education.

Exclusion criteria

1. History of severe somatic or brain organic diseases and craniocerebral trauma; 2. Abnormal brain structure or any MRI contraindications were found by magnetic resonance examination; 3. Those who do not cooperate or cannot effectively complete the experiment; 4. Drug, alcohol or other psychoactive substance abusers; 5. Pregnant, lactating or planned pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Wechsler Memory Scale0-8 weeksThe Wechsler Memory Scale score was used to evaluate the degree of cognitive function, and the lower the score, the more severe the cognitive function impairment. The scoring threshold is 70 points. A lower score means more severe cognitive impairment.

Countries

China

Contacts

Primary ContactHu ShaoHua, M.D
dorhushaohua@zju.deu.cn13357169115
Backup ContactWang DanDan
851176155@qq.com18867132330

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026